Brain Chip for Depression Treatment to be Tested on Humans in the UK
Neurotechnology has seen remarkable advancements in recent years. According to Precedence Research, the global neurotechnology market, valued at $15.3 billion in 2024, is projected to reach $52.86 billion by 2034.
In the UK, clinical trials are set to begin in March 2025 for a brain chip designed to treat anxiety and depression. This implant will utilize ultrasonic pulses to stimulate brain neurons. Over £6.5 million has been allocated to these trials, involving 30 patients and funded by the UK's Advanced Research and Invention Agency (ARIA).
How the New Technology Will Treat Depression
Scientists at the UK's National Health Service (NHS) plan to use ultrasound to modulate brain activity. This will be achieved through a brain-computer interface (BCI), a system that facilitates communication between the human brain and an electronic device. The device, named Forest 1, was developed for the NHS by US-based Forest Neurotech.
The clinical trials will include patients who have undergone a temporary craniectomy (removal of a portion of the skull) to alleviate intracranial pressure. The NHS has indicated that this particular group was chosen to allow testing of the device without requiring additional surgical procedures.
The Forest 1 implant will be placed in the surgically created opening in the skull for two hours. During this time, it will detect any changes in cerebral blood flow. These changes will be recorded, generating detailed 3D maps of brain activity for neurobiologists. When necessary, the device can also be used to stimulate specific neuron clusters.
Trial Timeline
The initial phase, involving regulatory approvals, is scheduled to commence in March 2025. Following this, Forest Neurotech will proceed with the clinical trials, which are expected to last until 2028.
"Neurotechnology has the potential to benefit a much broader range of individuals than we previously imagined. Treating depression, epilepsy, addiction, eating disorders – the potential applications are vast," said ARIA program director Jacques Carolan, as quoted by The Guardian.
ARIA describes Forest 1 as the "most advanced" brain-computer interface to date. Its ability to target multiple brain regions simultaneously sets it apart. Scientists believe this technology holds promise for patients with various conditions, as these conditions often involve abnormalities in multiple brain areas rather than a single, localized spot.
One potential challenge during testing is the risk of tissue overheating. To mitigate this, neurobiologists will closely monitor the intensity and duration of ultrasound application. This will minimize the risk of heat buildup while still achieving the desired therapeutic effect.
